about
Erlotinib for advanced pancreatic cancerDownregulation of galectin-3 by EGF mediates the apoptosis of HepG2 cellsEGF receptor-targeted nanocarriers for enhanced cancer treatmentMolecular pathology of lung cancer: key to personalized medicine.Polymeric nanoparticles for targeted treatment in oncology: current insightsProteomic data from human cell cultures refine mechanisms of chaperone-mediated protein homeostasisThe pros and cons of phytoestrogensEGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cellsNanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancerSingle cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell linesThe tyrosine kinase c-Src directly mediates growth factor-induced Notch-1 and Furin interaction and Notch-1 activation in pancreatic cancer cellsA neutralizing RNA aptamer against EGFR causes selective apoptotic cell deathPIKE mediates EGFR proliferative signaling in squamous cell carcinoma cells.Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.GEP100/Arf6 is required for epidermal growth factor-induced ERK/Rac1 signaling and cell migration in human hepatoma HepG2 cellsPotential upstream regulators of cannabinoid receptor 1 signaling in prostate cancer: a Bayesian network analysis of data from a tissue microarray.Decoding Cellular Dynamics in Epidermal Growth Factor Signaling Using a New Pathway-Based Integration Approach for Proteomics and Transcriptomics Data.EGF signalling and rapamycin-mediated mTOR inhibition in glioblastoma multiforme evaluated by phospho-specific flow cytometry.MOXIBUSTION ALLEVIATES GASTRIC PRECANCEROUS LESIONS IN RATS BY PROMOTING CELL APOPTOSIS AND INHIBITING PROLIFERATION-RELATED ONCOGENES.Systemic sclerosis immunoglobulin induces growth and a pro-fibrotic state in vascular smooth muscle cells through the epidermal growth factor receptor.Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model systemTumour Cannabinoid CB(1) receptor and phosphorylated epidermal growth factor receptor expression are additive prognostic markers for prostate cancer.Structure-based virtual screening and molecular docking for the identification of potential multi-targeted inhibitors against breast cancer.Dr. PIAS: an integrative system for assessing the druggability of protein-protein interactions.Geldanamycin analog 17-DMAG limits apoptosis in human peripheral blood cells by inhibition of p53 activation and its interaction with heat-shock protein 90 kDa after exposure to ionizing radiationGenistein increases epidermal growth factor receptor signaling and promotes tumor progression in advanced human prostate cancerComparison of stem/progenitor cell number and transcriptomic profile in the mammary tissue of dairy and beef breed heifers.EGF receptor exposed to oxidative stress acquires abnormal phosphorylation and aberrant activated conformation that impairs canonical dimerizationPKN1 modulates TGFβ and EGF signaling in HEC-1-A endometrial cancer cell line.LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling.Insight into nanoparticle cellular uptake and intracellular targetingEGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells.Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice.Bioengineering strategies for designing targeted cancer therapiesDifferences in molecular genetics between pediatric and adult malignant astrocytomas: age matters.A novel multifunctional nanocomposite C225-conjugated Fe3O4/Ag enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy.YM155 induces EGFR suppression in pancreatic cancer cells.Hydrogen sulfide targets EGFR Cys797/Cys798 residues to induce Na(+)/K(+)-ATPase endocytosis and inhibition in renal tubular epithelial cells and increase sodium excretion in chronic salt-loaded ratsPhospho-Akt immunoreactivity in prostate cancer: relationship to disease severity and outcome, Ki67 and phosphorylated EGFR expression
P2860
Q24186983-C52C321D-682B-408F-9BA2-302B71FBDA56Q24339487-FC9961C1-7B77-45DB-9B9E-FF7E3D7573AAQ27013001-12296CA5-BECC-41B2-9149-E8A725AAEE01Q27691299-3D4FD396-128F-497F-802F-55687A70B5B5Q28087243-6B16FD28-6136-4C04-A93C-A2470875EE9DQ28286034-5FD09860-F92C-46F5-9A5A-499987E69D7CQ28387746-79C6F710-091B-4CD4-8FBA-84F3B8788D59Q28478401-4AD307FE-E029-4852-8EB4-01FB0D7F05FBQ28480835-536A42A1-D5A2-465B-83D4-91B4B48B14A4Q28483475-B22A134F-8FAC-46CE-8867-0E8CA1790DC2Q28730831-EDDFAE05-CC7B-48D3-862C-1247EFA7FA78Q28740749-B1AEA8D2-4CF9-4318-8CCF-7F4D4569D101Q30010164-1FB9E076-8C71-43A8-A4B8-1DD9010F3C83Q30366990-5B09D3F2-BD03-416D-A562-DCB505D34A56Q30403317-1C466141-05D0-4E4F-A4B7-03DF099A9D05Q30426476-3DA41667-B0CE-47C8-9355-812ACF9C0EA1Q30830112-33846623-4ADD-4B9A-B43F-DFE654C81C8FQ31037462-452741C9-9306-4188-9D75-4091BE3AE7E7Q31110612-DA081EB4-FBA9-417F-ACC4-6DF7CD0D198BQ33732857-1D17F641-0FE5-45D7-A643-A1C1C976E733Q33754081-78AF0BC3-3002-4B16-8DC1-8E8FA7FD01B1Q33769117-9D48360E-0D92-460E-B4CC-500FD4B3ED47Q33784488-3D569365-E84D-480D-9B20-AE21693EFCDEQ33812240-72EAF972-F7A6-4A14-A703-54F97B3F5995Q33814963-727BF7F9-1E78-4295-A198-EABBB49CEBBAQ33825349-BA866E2D-CB15-4BE6-AEA7-184DF42A3FCFQ33908395-4E97650E-DB82-4D00-A486-678EF3E01191Q33917475-0B676EBD-E5E3-4D44-82A6-2B05B10B44DEQ33996985-28FC4666-1A50-4CD5-A99A-45FCDCEFFA1BQ34028421-FAE167A6-F031-449D-AE31-A5C683714796Q34081759-14CBC878-659E-445D-9A7C-566FB18A184DQ34127625-BEC06215-5744-4086-93A6-CC6ADAF59239Q34149887-FC77C02E-BAED-4C6B-9D1B-3C8C1C7F1DA2Q34181861-D142071F-5966-487E-AB6B-9A7B4FFAE639Q34194191-2796EFDF-6F2B-444F-BBC6-1A2CF421B582Q34286305-1BA1F164-D56C-47A1-A265-27E4FD66B510Q34308176-A5C259C2-322C-4C52-8B0A-B354BB9FF22CQ34313903-478505F8-94E7-4320-9564-D8AE63B998D7Q34431778-CA658BA4-A37F-4B08-A151-F8477792E2F5Q34469245-E7E48F5A-BE69-4177-8BE1-15C1D2E33033
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
EGFR signaling and drug discovery.
@ast
EGFR signaling and drug discovery.
@en
EGFR signaling and drug discovery.
@nl
type
label
EGFR signaling and drug discovery.
@ast
EGFR signaling and drug discovery.
@en
EGFR signaling and drug discovery.
@nl
prefLabel
EGFR signaling and drug discovery.
@ast
EGFR signaling and drug discovery.
@en
EGFR signaling and drug discovery.
@nl
P356
P1433
P1476
EGFR signaling and drug discovery.
@en
P2093
Georg Lurje
P304
P356
10.1159/000279388
P577
2009-01-01T00:00:00Z